Nautilus Biotechnology, Inc. NAUT

Technology SIC 3826 - Laboratory Analytical Instruments Nasdaq

On June 9, 2021 (the "Closing Date"), Nautilus Biotechnology, Inc., a Delaware corporation (f/k/a ARYA Sciences Acquisition Corp III ("ARYA")), consummated the business combination (the "Business Combination") pursuant to the terms of that certain Business Combination Agreement, dated as of February 7, 2021 (the "Business Combination Agreement"), by and among ARYA, Mako Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of ARYA ("Mako Merger Sub"), and Nautilus Subsidiary, Inc., a Delaware corporation (f/k/a Nautilus Biotechnology, Inc.) ("Legacy Nautilus"). The Business Combination Agreement provided for, among other things, (i) the domestication of ARYA as a corporation incorporated under the laws of the State of Delaware, upon which ARYA changed its name to "Nautilus Biotechnology, Inc." (together with its consolidated subsidiary, the "Company" "New Nautilus" or "Nautilus") and (ii) the merger of Mako Merger Sub with and into Legacy Nautilus (the "Merger"), with Legacy Nautilus as the surviving company in the Merger and, after giving effect to such Merger, Legacy Nautilus becoming a wholly-owned subsidiary of New Nautilus.

Last close 0.90 2026-09-04
Market cap $115.0M 2026-03-31 share count
52-week range 0.65 - 4.31

Valuation FY2025 figures against the last close

P/S
P/E
P/FCF
EV/EBITDA
Dividend yield
Diluted EPS-0.47

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
R&D $41.1M$50.5M$47.3M$37.7M$29.4M$12.4M
SG&A $25.7M$31.0M$28.9M$25.9M$21.1M$3.3M
Total operating expenses $66.8M$81.5M$76.2M$63.6M$50.5M$15.7M
Pre-tax income -$59.0M-$70.8M-$63.7M-$57.9M-$50.3M-$15.6M
Income tax $0$0$0$0$0$0
Net income -$59.0M-$70.8M-$63.7M-$57.9M-$50.3M-$15.6M
EPS, basic -0.47-0.56-0.51-0.46-0.60-0.54
EPS, diluted -0.47-0.56-0.51-0.46-0.60-0.54
Shares, diluted (wtd. avg.) $126.3M$125.4M$124.9M$124.6M$84.5M$29.1M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents $12.4M$27.6M$20.4M$115.5M$186.5M$37.2M$595.0K
Short-term investments $91.0M$102.2M$154.0M$69.9M$160.1M$40.1M
Total current assets $106.0M$132.8M$176.8M$187.2M$349.2M$77.7M
Property, plant and equipment $3.5M$4.1M$4.3M$3.7M$2.5M$1.4M
Total assets $191.1M$242.7M$305.6M$350.1M$398.4M$85.0M
Accounts payable $943.0K$987.0K$1.6M$1.3M$1.7M$470.0K
Total current liabilities $8.0M$7.6M$9.1M$6.8M$5.8M$3.0M
Total liabilities $34.1M$34.0M$40.2M$35.1M$34.9M$6.3M
Retained earnings -$332.0M-$273.0M-$202.2M-$138.6M-$80.6M-$30.3M
Total equity $157.0M$208.7M$265.4M$314.9M$363.6M-$29.7M-$14.5M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating cash flow -$50.7M-$59.1M-$51.7M-$45.8M-$39.2M-$14.0M
Depreciation and amortisation $1.7M$2.0M$1.8M$1.2M$1.0M$710.0K
Stock-based compensation $6.8M$12.7M$12.1M$10.4M$7.9M$369.0K
Capital expenditure $1.3M$2.1M$2.4M$2.3M$2.3M$921.0K
Investing cash flow $35.2M$66.2M-$43.7M-$25.7M-$139.0M-$25.3M
Financing cash flow $214.0K$1.1M$368.0K$562.0K$327.4M$75.9M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001808805-26-000011.

Others in SIC 3826

TickerCompanyMarket capP/ERevenue growth
A AGILENT TECHNOLOGIES, INC. $42.53B 33.0x 6.7%
WAT WATERS CORP /DE/ $40.22B 38.0x 7.0%
ILMN ILLUMINA, INC. $32.95B 40.0x -0.7%
MTD METTLER TOLEDO INTERNATIONAL INC/ $26.95B 32.0x 4.0%
RVTY REVVITY, INC. $14.53B 62.9x 3.7%
BIO BIO-RAD LABORATORIES, INC. $10.33B 13.9x 0.7%
AVTR Avantor, Inc. $10.22B -3.4%
BRKR BRUKER CORP $8.88B 2.1%